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 INTRODUCTION 
                Sexually transmitted infections (STIs) are a major global cause of 
acute illness, infertility, long term morbidity and mortality, with severe medical 
and psychological consequences of millions of men, women and infants1. STIs 
most commonly affect people aged between  15 to 44 years. 
             In 2006, 1,030,911 Chlamydial infections and 3,58,366 Gonococcal 
infections were reported to CDC from 50 states and the districts of Columbia in 
United states2,3. Chlamydia trachomatis and Neisseria gonorrhoeae remain the 
two most preventable causes of human infertility4. Untreated Gonococcal and 
Chlamydial infections in women will result in pelvic inflammatory disease in 
upto 40% of cases. One in four of these will result in infertility 5. 
              Demographic risk factors for the acquistion of gonorrhoeae include 
migration of population, unemployment, lack of education, poverty, early onset 
of sexual activity,unmarried marital status,past history of gonorrhoeae,illicit 
drug use and now commercial sex have been operative universally, but more 
severely in certain societies and countries.   
           Among several risk factors for chlamydial infection age is the most 
important one. Other risk factors include previous chlamydial infection, recent 
change in partner, a symptomatic partner, failure to use barrier contraceptives, 
low socioeconomic status,use of oral contraceptives and the coinfection with 
gonorrhoeae 6,7.The highest infection rates are found in sexually active 
adolescents where approximately 15% of girls and 5-10% of boys are infected 
6,7. 
           Since publications of CDC’s 1993 guidelines NAATs have been 
introduced as critical new tools to diagnose and treat Chlamydia trachomatis 
and Neiserria gonorrhoeae infections 8. 
               Nucleic acid amplification tests (NAATs) have enabled the 
epidemiology of chlamydia to become clearer even in difficult to reach 
population.The recent development of  NAATs for gonorrhoeae have also 
enabled the epidemiology of gonorrhoeae to become clearer, though culture is 
still the most commonly  used diagnostic method 9-11. 
               The Amplicor Chlamydia trachomatis / Neisseria gonorrhoeae (CT 
/NG) test is a qualitative in vitro test for the detection of Chlamydia 
trachomatis and Neisseria gonorrhoeae in urine from both sexes,in 
endocervical swab specimens from females and in urethral swab specimens 
from males. The test utilizes Polymerase Chain Reaction (PCR) nucleic acid 
amplification and nucleic acid hybridization for the detection of C.trachomatis 
and  N.gonorrhoeae in urogenital specimens. 
 
 
  
REVIEW OF LITERATURE 
            Sexually transmitted infections (STIs) are a major cause of morbidity in 
the developed as well as developing countries which also result in lot of 
psychological morbidity in the young sexually active adults. The World Bank 
estimates that STIs, excluding AIDS, are the second leading cause of healthy 
life lost amongst women aged between 15 and 44 in the developing world 12. 
GONOCOCCAL INFECTIONS 
          Gonorrhoeae is a common and universally  encountered sexually 
transmitted bacterial disease, caused by a gram negative diplococcus, Neisseria 
gonorrhoeae. 
Morphology of Neisseria gonorrhoeae 
        Gonococci are gram negative, aerobic, nonmotile, nonsporing  cocci 
typically arranged in pairs (diplococci) with adjacent sides concave, typically 
reniform or pear shaped. In urethral discharges, they are generally present 
intracellularly within polymorphonuclear leucocytes. 
Prevalence of Gonorrhoeae:  
           Gonorrhoeae is a well recognized public health problem. It is the second 
most common bacterial STI in the world next to Chlamydia  trachomatis 
infection.WHO estimates that gonorrhoeae accounted for 18% of the new cases 
of curable STIs Worldwide in 1999 with 62 million new cases amongst adults 
aged 15 to 49 years 1. 
              Numerous surveys conducted in recent years have shown that 
gonorrhoeae is the most common cause of male urethritis accounting for 
approximately 53-80% of the all STD cases.In India also, gonorrhoeae is a 
major public health problem with majority of the reported cases occurring in 
the 20-24 years age group 13-16. 
               In India incidence of gonorrhoeae vary from  3% to 19% among the 
STD clinic attendees from different regions 14-19.In a survey of women 
attending an STD clinic in Mumbai in 1996, 9.7% were positive for gonococcal 
infections 20.The apparent ratio of male to female cases  is 10:1, with 80-90% 
men acquiring infection from commercial sex workers 21. 
         Genital gonorrhoeae may be asymptomatic in both men and women, but 
it is more frequently silent  in women. 30% to 80% of female cases of 
gonorrhoeae are asymptomatic in comparison  with less than 5% of infected 
men 22. 
Clinical features 
        The incubation period  ranges from 1 to 14 days but majority of men 
develop symptoms within 2 to 5 days 23. Neisseria gonorrhoeae has a 
predilection for columnar and  cuboidal  epithelium. Asymptomatic infection 
occurs at urethra,endocervix, rectum and  pharynx.                                                                   
              Acute Gonorrhoeae in men presents as acute anterior urethritis.If  
prompt treatment is not initiated, posterior urethritis may ensue in 10-14 
days.Acute gonococcal infection may involve the glands of Tyson, 
paraurethral, periurethral and Littre’s glands and present as acute tysonitis, 
acute littritis, inflammation of paraurethral and periurethral glands and 
gonococcal balanitis.Acute cowperitis, prostatitis, seminal vesiculitis and 
epididymitis are the other acute complications in males especially when the 
posterior urethra is affected.The patient may develop urethral  strictures, 
fistulae leading to watering can perenium, chronic littritis, cowperitis,  
prostatitis, seminal vesiculitis or epididymitis.  
          Uncomplicated  gonorrhoeae in women may remain asymptomatic in 
about 50 percent cases that may act as reservoir of infection. Acute gonococcal 
infection in females presents as endocervicitis, acute skenitis, acute 
bartholinitis, acute gonococcal vulvitis, gonococcal cystitis and trigonitis. 
            Pelvic inflammatory disease (PID) is the most common local 
complication accounting for 10 to 20 percent of cases with acute gonococcal 
infection 24.Complications include salpingitis, pyosalpinx, tubo-ovarian 
abscess, pelvic abscess, pelvic peritonitis.  PID is a serious health problem 
resulting in tubal infertility, ectopic pregnancies or chronic pelvic 
pain25.Organization of pus in the pelvis leads to adhesion between pelvic 
organs and intestines termed as frozen pelvis. Chronic urethritis, skenitis, 
bartholinitis and proctitis are the other complications in women. 
          Gonococcal  proctitis in males usually results from anal coitus in passive 
homosexuals and rectum is a frequent site of infection in 40 percent of 
homosexual men 26.In women, rectal mucosa is infected in 35% to 50%  of 
cases with gonococcal cervicitis.Pharyngeal gonorrhoeae is transmitted by 
orogenital contact and is more efficiently acquired by fellatio than by  
cunnilingus 27. Gonococcal conjunctivitis is a rare  entity in adults and often 
seen  in patients with concomitant anogenital gonorrhoeae as a consquence of 
direct contamination by fingers or towels. 
              In Disseminated gonococcal infection(DGI) the characteristic clinical 
findings include  suppurative arthritis and skin lesions. DGI is more common 
in females with a male to female ratio of 1:4 28. Risk factors for DGI include 
pregnancy, premenstrual period, pharyngeal gonorroheae 29 and complement 
deficiency. Most of the cases are caused by AHU auxotype(AHU-). 
         During pregnancy, there is a high risk of developing salpingitis and PID. 
Gonococcal chorioamnionitis may occur which  leads to septic abortions and 
also increases the risk of premature rupture of membranes, preterm births, 
prematurity, perinatal mortality or low birth weight 30.In Neonatal gonorrhoeae, 
the most frequent manifestation is Opthalmia neonatarum. 
Coinfection with C.trachomatis 
        Genital infection with Chlamydia trachomatis commonly accompanies 
gonococcal infection in 10-20% of men and  20-30% of women 31. 
A gene present on the gonococcal chromosome called the sac-4 gene has been 
postulated to increase the risk of developing mixed gonococcal and chlamydial 
infection. This gene confers stable complement factor c1q  dependent serum 
resistance.  The prevalence of the gene was 69.5% in gonococcal isolates  from 
patients with co-existing chlamydial infection compared with 57.9% from 
those without chlamydia 31. 
LABORATORY DIAGNOSIS  
       The sites for specimen collection in females include the endocervix, 
rectum, urethra and pharynx. In heterosexual males urethra and pharynx are the 
common sites affected. Specimens should be collected with dacron, rayon or 
polyethylene terephthalate (PET) swabs or sterile platinum loop 32. The 
specimen is transported in Amie’s or modified Stuart’s medium. 
Direct microscopy of stained smears 
      Gonococci are readily demonstrated in Gram stained smears as pink 
coloured  intracellular diplococci present within polymorphonuclear 
leucocytes.  
Culture  
         Culture is considered the ‘gold standard’ for the diagnosis of 
gonorrhoeae. Gonococci are fastidious organisms requiring enriched media for 
growth. They are aerobic and capnophilic. Optimum growth occurs at 35-36°C 
& pH between  7.2 and 7.6. 
         Gonococci grow on enriched, selective media like Modified Thayer-
Martin Media (MTM), Martin Lewis, New York City,Chacko-Nair Medium 
and GC-Lect-Medium33-34. Vancomycin and colistin inhibits gram +ve and 
gram –ve bacteria including saprophytic neisseriae species and nystatin, 
amphotericin-B are added to inhibit yeasts and moulds. Sensitivity of culture is 
reported between 80% and 95% with false negative results attributed to poor 
specimen storage, transport problems and inhibiting of growth by the 
components of selective media 35. 
         Gonococci form small, round, translucent, soft emulsifiable and convex 
colonies with fine granular surface and lobate crenated margins. The colonies 
types recognizable are upto T1-T4. 
Biochemical identification: In Oxidase test, a loopful of freshly prepared 
aqueous tetramethyl -p-phenylene diamine Hcl is poured over the colonies. 
Gonococci colonies turn pink within 10 seconds & rapidly deepening to purple. 
Gonococci is catalase positive.  It ferments glucose, but not 
maltose,sucrose,fructose or lactose producing acid but no gas. 
Direct Antigen Detection in Clinical Specimens 
Enzyme Immunoassay 
        Gonozyme test is a solid-phase enzyme immunoassay for the direct 
detection of gonococcal antigen in male urethral and female endocervical 
specimens 36. Antibiotic sensitivity determination cannot be performed by this 
system. 
Molecular techniques 
1).Nucleic acid probes:  A commercially available probe called ‘PACE’ 
(Probe assay chemiluminescence enhanced) has been developed for direct 
detection of gonococci in cervical and urethral specimens 37. 
2)Hybrid Capture II Test (HC II GC Test).  
3)Nucleic Acid Amplification Test (NAAT) 
            These tests enable the use of noninvasive specimens such as first void 
urine and self obtainable vaginal swabs for diagnostic testing and for screening 
of asymptomatic low-prevalence and hard to access populations. 
a)Polymerase chain reaction 
           This test amplifies target sequences on the 2.6 MDa (14.2kb) cryptic 
plasmid that is also represented on the gonococcal chromosome 38. Alternately, 
amplification of the target sequence within gonococcal 16S rRNA gene is also 
performed. Recently, Roche Molecular systems have developed a multiplex 
PCR-based test for N-gonorrhoeae and C.trachomatis that allows simultaneous 
amplification of both the targets 39. It is available in two formats. The fully 
automated COBAS amplicor CT/NG and the semiautomated AMPLICOR 
CT/NG microwell plate format tests. The sensitivity  from endocervical swab 
specimens is 92.4% and from female urine samples is 64.8%. The 
corresponding specificities are 99.5% and 99.8% respectively.  In symptomatic 
men, sensitivity is 94.1% for urine and 98.1% for urethral swabs and in 
asymptomatic men 42.3% and 73.1% respectively. The specificity is 98.9% for 
urethral swab specimens and 99.9% for urine samples in men. 
b)Ligase chain reaction 
            It is a rapid, highly sensitive non-culture method for gonococcal 
detection40. This technique exponentially amplifies targeted DNA sequences 
especially within twc cpacity genes(Opa-1 gene). 
4)DNA Hybridization Test This test utilize the 2.6 MDa gonococcal cryptic 
plasmid as radiolabelled  probe 41. It can detect as few as 100 colony forming 
gonococcal units and upto 0.1 pg of purified gonococcal plasmid DNA. 
Serological tests Gonococcal antibodies such as pilin, P.I. or P.II. antibodies 
can be detected. These tests include complement –fixation test, latex 
agglutination test, indirect immunofluorescence, radioimmuno-assay, indirect 
haemagglutination test, ELISA and western blotting. 
 
Treatment 
              The recommended treatment for uncomplicated gonococcal infection, 
is Inj. Ceftriaxone 250mg  IM as a single dose (or) cefixime 400mg orally 
single dose.The treatment of gonorrhoeae should be combined with 
Azithromycin 1g orally single dose or Doxycycline 100mg orally twice a day 
for 7 days for concomitant C. trachomatis infection 6. 
CHLAMYDIA TRACHOMATIS INFECTIONS 
         Chalmydia trachomatis is considered the most common sexually 
transmitted bacterial pathogen 42.  
Epidemiology 
          WHO estimates that 92 million new cases of Chlamydia occurred 
worldwide in 1999 amongst those aged 15 to 49 years 1.It is estimated that 85% 
women and 40% of men are  asymptomatic and therefore only detectable with 
screening programmes7. There are relatively few studies from India, but those 
that do exist found relatively high prevalence in selected populations.  
Morphology:  
                       Chlamydia trachomatis are small obligate intracellular bacteria 
and they contain DNA, RNA and ribosomes and make their own proteins and 
nucleic acids. They are nonmotile and are gram negative. The human C. 
trachomatis pathogens can be divided into atleast 15 serovars by 
microimmunofluorescent (Micro IF) test 43. A,B, Ba, C serovars are associated 
with hyperendemic blinding trachoma. The D to K Serovars commonly cause 
nongonococcal urethritis, conjunctivitis and infantile pneumonia.The L1 to L3 
serovars represent the LGV biovar. Species, serogroup and serovar specific 
antigens can be found on the MOMP membrane 44. 
Clinical features The most common manifestation is nongonococcal 
urethrtits (NGU) in men 7. NGU is diagnosed by demonstrating a 
‘significant’ number of PMNs in first -catch urine or a smear prepared 
from a urethral swab. C. trachomatis is responsible for 70% to 90% of 
Postgonococcal urethritis 45. Because of the high (>20%) double infection 
rate, CDC and WHO recommended that all case of gonorrhoeae be 
treated presumptively for Chlamydial infection46. Ascending Chlamydial 
infections can result in epididymitis.   
                   In the female, the most commonly affected site is the cervix, where 
the organism can cause a mucopurulent endocervicitis (MPC). Women with 
gonorrhoeae often have chlamydial infection. Double infection rates may be 
twice as high ( 35%-45%) as those observed in men. It is even more important 
to treat women with gonorrhoea for chlamydial infection as it reduces 
subsequent development of salpingitis 46. Chalmydia infection has been 
associated with sterile pyuria in young women. 
          10-40% of women with untreatable chlamydial infection develop 
symptomatic PID.  Post infection tubal damage is responsible for 30-40% cases 
of female infertility. Furthermore women who have had PID  are 6-10 times 
more likely to develop on ectopic pregnancy. C. trachomatis is also associated 
with the Fitz–Hugh Curtis Syndrome(Perihepatitis) a complication of 
salpingitis.Chalmydia positive women may develop postpartum endometritis 
after vaginal delivery. Some studies found an association with foetal wastage 
and prematurity 47.Other manifestations include bartholinitis, arthritis and 
dermatitis .                                       
Laboratory diagnosis 
Direct Microscopy.  For resuspension of the centrifuged  sediment of a 10 to 
15 ml of first catch urine,the usual criteria for diagnosis is 15 or more PMNs 
per X 400 high -power field and for a smear obtained by urethral swabbing the 
cut  off is 5 or more PMNs per X 1000 field 7. In females, >30 PMN leucocytes 
per OIF or gram stained smears of cervical mucus is suggestive of chalmydial 
cervicitis. Other stains include Giemsa and Iodine stains. 
 Tissue culture The gold standard in the diagnosis of genital chlamydial 
infection is tissue culture. Irradiated or cycloheximide treated McCoy cells, 
BHK-21, Hela –229 have been used successfully for the isolation of C. 
trachomatis 48.Confirmation of the isolates is done either by Giemsa or Iodine 
stains or by the use of fluorescein labelled monoclonal antibodies. 
Antigen detection 1) Direct immunofluorescence assay (DFA) 
This is a rapid diagnostic test carried out on clinical specimens using 
monoclonal fluorescein labelled anti-chalmydial antibodies against the species 
specific epitope of major outer membrane protein (MOMP) or genus specific 
lipopolycaccharide (LPS)49.                         
 2) Enzyme –linked immunosorbent assay (ELISA) These products detect 
chlamydial LPS, which is more soluble than the MOMP. The tests use either 
monoclonal or polyclonal antibodies to LPS and thus theoretically could detect 
all chalmydia. 
Rapid tests 
        There are three commercially available rapid assays,which are quite 
expensive but give results within 30 minutes and thereafter are useful in field 
conditions. They are as follows Sure cell Chalmydia test,Clear view Chalmydia 
test ,The test pack Chalmydia test 50. 
Detection of DNA in clinical specimens 
i)DNA probes Probe assay Chemiluminescence enhanced (PACE) test utilizes 
a nonisotopic DNA probe (a single stranded DNA labelled with acridinium 
ester) for the detection of specific rRNA of C-trachomatis in endocervical and 
urethral specimens 51. 
 ii) Polymerase chain reaction(PCR) 
 Plasmid DNA amplification has become the most popular approach in 
PCR of C. trachomatis. A variety of amplification targets have been used for 
PCR including the common cryptic plasmid, which was found to be the best52. 
A number of studies  comparing PCR 52 with the other diagnostic methods  
showed PCR as more sensitive than culture (99% vs 78%) and the specificity 
was above 99%. 
           The results of a recent study indicate that Amplicor CT/NG multiplex  
PCR test performed on urine in men provides a highly sensitive, specific and 
robust method for the diagnosis of both C.trachomatis and N.gonorrhoeae for 
the early detection of both symptomatic and asymptomatic individuals53. 
Multiplex PCR developed by Mahoney et al was 100% sensitive and specific 
for C. trachomatis 54.Depending on the prevalence of infection, pooling of the 
first catch urine samples for PCR testing is more economical than testing 
individual samples 55. 
iii)Ligase chain reaction The sensitivity of LCR performed on endocervical 
specimens has ranged from 87% to 97% and in female FVU, the sensitivity 
was equal to cervical culture 55.For FVU in men, the test has a sensitivity of 
approximately 90-96% in detection of chlamydial urethritis 56. 
iv)Other tests a)Gen Probe Amplified CT (AMP CT) assay uses the 
transcription mediated amplification and hybridisation technique to detect C. 
trachomatis rRNA in endocervical and urinary specimens 58. b) Q-beta  
replicase amplified hybridation assay (Gen Trak, Inc)59. 
Serology                                                                                                                                     
Serological assays may be useful in the detection of C. trachomatis infections 
of the genital tract. However 45-65% of patients may have antibodies resulting 
from a past infection and the traditional approach for the detection  of four –
fold rise in titre does not seem to be applicable.Elevated titres are detected by  
EIA or complement fixation (CF). The detection of IgM antibodies may also be 
helpful in establishing acute Chlamydial infections of the genital tract.The 
Calbiotech Inc, Chlamydia trachomatis IgM ELISA test system detects IgM 
class antibodies to C.trachomatis human serum or plasma 60. 
Treatment  For lower genital tract infections, Azithromyin 1g orally single 
dose or doxycyline  100mg orally bid X 1 week are the treatment of choice6.  
Gonococcal and Chlamydial Infections in HIV- Infected Patients 
  Classical STIs, both ulcerative and non-ulcerative, could facilitate HIV-1 
transmission by increasing either the infectiousness of the index case, the 
susceptibility of the partner, or both 61-62.Wasserheit has  called the relationship 
between HIV and STIs as epidemiological synergy62. 
Ho JL, et al showed that chlamydia trachomatis increase the replication of 
HIV-1, probably through the generation of reactive oxygen products and 
cytokines secreted by granulocytes 63. Moss et al detected HIV-1 RNA in the 
urethra more frequently in patients with coexistent gonococcal urethritis than in 
controls 64. 
                 POLYMERASE CHAIN REACTION (PCR) 
      PCR, the Polymerase chain reaction was discovered by Kary Mullis in 
198365. Thermostable Taq DNA Polymerase, the enzyme used in PCR was 
chosen as the molecule of the year 1989. 
PRINCIPLE OF PCR 66 
     The purpose of a PCR is to make a huge number of copies of a gene. It is a 
Nucleic acid amplification test . In PCR there are three major steps which are 
repeated for 30 or 40 cycles. This is done on a automated thermal cycler, which 
can  heat and cool the tubes with the reaction mixture in a very short time. 
1. Denaturation at 94°C - During the denaturation, the double strand 
melts open to single strand DNA. 
2. Annealing at 54°C-when the temperature is cooled to 54°C, the 
oligonucleotide primers which are added to the mixture designate the 
boundaries of the DNA strand being duplicated. 
3. Extension at 72°C- This is the ideal temperature for the polymerase 
enzyme. The thermostable Taq DNA polymerase enzyme in presence 
of all the four essential deoxy nucleoside triphosphates including 
deoxyadenosine, deoxyguanosine, deoxycytidine, dexoyuridine ( in 
place of deoxy thymidine) triphosphates, extends the annealed 
primers along the target template. In a thermal cylcer, this process is 
automatically repeated 30-40 times for 2 to 4 hours. 
The thermostable enzyme Taq DNA Polymerase was isolated from 
Thermus aquaticus growing in hot springs .This enzyme acts best at 72°C 
and the denaturation temperature of  90°C does not destroy its enzymatic 
activity. Other thermostable enzymes are Pflu DNA polymerase from 
pyrococcus furiosus and Vent polymerase from Thermococcus litoralis. 
 
DIFFERENT SCHEMES OF PCR67 
1. Reverse transcriptase PCR(RT-PCR)-The formation of 
complementary or copy DNA from RNA is the first step of a usually two 
step process of RT-PCR.The second major step is the amplification  of c-
DNA sequence using primers specific for the DNA sequence 67.  
2.  Multiplex PCR: It is used for simultaneous detection of two or more 
organisms. AMPLICOR CT/NG PCR is multiplex PCR which  
simultaneously detects gonococcal and chlamydial infections69. 
Multiplex PCR has been developed for simultaneous detection of 
Treponema pallidum, Haemophilus ducreyi and herpes simplex virus 
types 1 and 2 for the diagnosis of genital ulcers 68. 
3. Real time PCR-It is characterized by the point in time during cycling 
when amplification of the PCR product of interest is first detected rather 
than the amount of the PCR product of interest which is accumulated at 
the end-point after PCR  which contained a large number of cycles 67. 
4.  Inverse PCR – functions to clone sequences flanking a known 
sequences. Flanking DNA sequences are digested  and ligated to 
generate cicular DNA.PCR primers pointing away from the known 
sequences are then employed to amplify the flanking sequences 67. 
5. Anchored PCR It will utilize only one primer instead of two primers. In 
this technique, only one strand will be copied first, after which Poly –G 
tail will be attached at the end of this new strand.This new strand  then 
becomes template using anchor primer with Poly-C sequence for the 
daughter strand . In the next cycle, both original and anchored primer 
will be used for amplification 67.  
6. Nested PCR It requires two sets of primers which are used to amplify a 
specific DNA fragment using two separate runs of PCR.The second pair 
of primers function to amplify a smaller specific DNA fragment located 
within the first PCR product67. 
7.  Long PCR  is a PCR in which extended or longer than standard PCR, 
measuring over 5 kilobases (frequently over 10kb)67. 
8.  Colony PCR- screening of bacterial (E-Coli) or yeast  clones for correct 
ligation or plasmid products done 67.  
9. Hot start PCR –It allows the inhibition of polymerase activity during 
PCR reaction preparation thereby reduces nonspecific amplification and 
increases PCR product target yield 67. 
10. OTHER TYPES-Amplified Fragment Length Polymorphism PCR 
(AFLP –PCR), Alu PCR, Asymmetric PCR, Optimizing PCR, Touch 
down  PCR are the other types 67. 
                      Allele specific PCR,Assembly PCR,Helicase dependent 
amplification,Intersequence-specific PCR(ISSR), Insitu PCR, Ligation 
mediated PCR,Methylation Specific PCR(MSP),Miniprimer PCR,Multiplex-
ligation dependent Probe Amplification(MLPA),Overlap-extension 
PCR,Quantitative PCR(Q-PCR),Solid phase PCR, TAIL-PCR(thermal 
asymmetric interlaced PCR),PAN-AC,Universal fast walking are the other 
variants 65. 
THE AMPLICOR CHLAMYDIA TRACHOMATIS / NEISSERIA  
                        GONORRHOEAE (CT /NG) PCR TEST 69 
             The AMPLICOR CT /NG test is a qualitative in vitro test for the 
detection of Chlamydia trachomatis and / or  Neisseria gonorrhoeae in urine 
from both sexes,in endocervical swab specimens from females, and in urethral 
swab specimens from males.The test utilizes Polymerase chain reaction (PCR) 
nucleic acid amplification and nucleic acid hybridization for the detection of C. 
trachomatis and for Neisseria  gonorrhoeae in urogenital specimens. 
       It consist of the following kits-Specimen preparation kit,amplification 
kit,detection kit for C.trachomatis, Neisseria gonorrhoeae and internal control , 
STD swab specimen collection and transport kit. 
 
 
PRINCIPLES OF THE PROCEDURE 
The AMPLICOR  CT /NG Test is based on four major processes. 
a) Specimen Preparation. 
b) PCR amplification of target DNA using biotinylated primers 70. 
c) Hybridisation of the amplified products to oligonuculeotide probes 
specific to targets. 
d) Detection of the probe -bound amplified products by color formation. 
         The AMPLICOR CT /NG  Test is a multiplex assay that permits the 
simultaneous amplification of C. trachomatis target DNA,  N. gonorrhoeae 
target DNA and Internal Control (IC) DNA. The detection of CT /NG IC must 
be performed when testing swab specimens collected and transported with the 
AMPLICOR  STD swab specimen collection and transport kit. 
SPECIMEN PREPARATION 
      The only acceptable specimens are 
a) Urine specimens (male and female) transported in clean polypropylene  
containers without  preservatives. 
b) Female endocervical and male urethral swab specimens collected and 
transported using the AMPLICOR STD Swab specimen collection and 
transport kit. 
 
 
A. URINE SPECIMENS 
            Patient must not have urinated during the previous 2 hours. 
1. Collect 10-15ml of first catch urine into a clean polypropylene container 
without preservatives. 
2. Urine specimens are stable for 24 hours at room temperature. Urine 
specimens that will not be processed within 24 hours of collection can be 
stored at 2-8°C but must be processed within 7 days of collection. Urine 
specimens that cannot be processed within 7 days of collection can be 
stored at -20° C or colder for upto 2 months. 
B.  SWAB SPECIMENS 
       Swabs are collected in AMPLICOR Specimen transport medium 
(STM). 
1. Remove mucus from the ectocervix and insert the large swab into the 
endocervical canal ,rotate for 3-5 seconds and withdraw, avoiding 
contact with vaginal surface. 
2. Place the swab in the AMPLICOR STM tube,shake vigorously the swab 
in the liquid for 15 seconds.Remove the swab and excess mucus in it and 
discard. 
3. Label the transport  tubes approximately. Swab specimens are stable at  
room temperature for 10 days. 
SPECIMEN PREPARATION: Epithelial cells, leucocytes and associated C. 
trachomatis and N.gonorrhoea cells, collected  on swabs or pelleted from urine, 
are treated with a detergent  solution to release both the Chlamydial DNA 
contained in Chlamydial reticulate bodes and the Neisserial DNA. A second 
detergent  solution is then added to prepare the lysed specimen for 
amplification. 
URINE SPECIMENS 
           Using a Sterile Pipette tip, add 500µL of CT/NG urine wash to the 
appropriate number of 2 ml Polypropylene tubes.Vortex urine thoroughly (3-10 
seconds)Using a pipette, with an aerosol barrier tip, add 500µL of well mixed 
specimen to the appropriate tube containing CT/NG urine wash and mix well 
by vortexing.Incubate at 37°C for 15 minutes. Centrifuge at >12,500 X g for 5 
minutes.Pour off specimen and blot each tube on a separate sheet of absorbent 
paper. 
           Add 250 µL of CT/NG LYS to each tube. Recap tubes and mix well by 
vortexing. Incubate tubes for 15 minutes at room temperature.Add 250 µL 
CT/NG DIL to each tube. Recap tubes and mix well by vortexing.Centrifuge 
tubes for 10 minutes at >12,500xg .Transfer 50 µL of the supernatant  to the 
appropriate tube containing working master mix. 
 
 
REAGENT PREPARATION 
 Prepare working master mix (MMX) by adding 100 µL of  CT/NG IC to 
one vial of CT/NG MMX. Add 50 µL of working master mix into each 
reaction  tube. CT/NG mastermix consists of Taq DNA Polymerase enzyme, 
deoxyribonucleotides- d-UTP, dATP, dCTP, dGTP, Amperase (Uracil - N-
glycosylase) enzyme,biotinylated CP24 and CP27 primers,  sodium azide,  Tris 
–Hcl buffer, EDTA, 100mM potassium chloride and glycerol. 
C. CONTROL PREPARATION  
            CT (+) C serves as the positive control for the CT MWP and the 
negative control for the NG MWP. The tube, labelled NG (+)C serves as the 
positive control for the NG MWP and the negative control for the CT MWP. 
Therefore, both the CT and NG controls must be prepared even if specimens 
will be tested for CT or NG only. 
PCR AMPLIFICATION 
           Target Amplification-The AMPLICOR  CT/NG test uses the primers 
cryptic plasmids CP24 and CP27 to define a  DNA sequence of approximately 
207 nucleotides within the cryptic plasmid of C. trachomatis  and for 
N.gonorrhoeae uses the primers SSO1 and SSO2 to define a sequence of 201 
nucleotides within the putative cytosine DNA methyltransferase gene 71. The 
processed specimens are added to the amplification  mixture in reaction tubes 
in which PCR takes place. The thermal cycler heats the reaction mixture in the 
tube to denature the double standard DNA helix  and expose the primer target 
sequences. As the mixture cools, the biotinylated primers CP24 and CP27 
anneal to the C. trachomatis and internal control target DNA, and the 
biotinylated primers SSO1 and SSO2 anneal to the N. gonorrhoeae target 
DNA. 
         The thermostable DNA Polymerase, Taq Polymerase, in the presence of 
excess deoxynucleoside triphosphate (dNTPs), including deoxyadenosine, 
deoxyguanosine, deoxycytidine (in place of deoxy thymidine) triphosphates, 
extends the annealed primers along the target templates to produce a DNA 
sequence termed as amplicon. AMPLICON can be distinguished from native 
DNA because it contains dUTP. This process is repeated for a number of 
cycles, each cycles effectively doubling the amount of amplicon. 
INTERNAL CONTROL AMPLIFICATION: 
         The CT/NG Internal control has been added to the AMPLICOR CT/NG 
test to identify processed specimen containing  substances that may interfere 
with PCR amplification. 
SELECTIVE AMPLIFICATION 
          Selective Amplification of target DNA from the clinical specimen is 
achieved in the AMPLICOR CT/NG test by the use of AMPErase (uracil-N-
glycosylase) enzyme72 and deoxyuridine triphosphate (dUTP). AMPErase 
enzyme recognizes and catalyses the destruction of DNA strands containing 
deoxyuridine, but not strains of target DNA containing deoxythymidine. 
Amperase enzyme below 55°C at the start of the test degrades any prior 
contaminating amplicon at C1 position of deoxyuridine. 
        Following amplification, any residual enzyme is denatured by the addition 
of the denaturation solution, thereby, preventing the degradation of any target 
amplicon.  
AMPLIFICATION AND DETECTION 
       Place the Tray /Retainer Assembly into the GeneAmp 9700 thermal cycler 
sample block.Program the Applied Biosystems Gene Amp PCR System 9700 
as follows 
     Hold Program :2 min50°C ,Hold Program :5 min 94°C.  Cycle Program (36 
Cycles) Denaturation-20 Sec 93°C;  Annealing -60 Sec  61°C; Extension - 
40 Sec 71°C;  Hold Program-5 min 72°C;Hold Program-72°C Forever. 
             Start the METHOD Programme. The Program runs approximately 2 
hours. Specimens may be removed at any time during the final HOLD 
program, but must be removed within 24 hours.Immediately add 100µ L of DN 
and incubate for 10 minutes at room temperature. Store denature AMPLICON 
at room temperature for 2 hours, but after two hours,store  at 2-8°C for upto 
one week. 
 
 
HYBRIDISATION REACTION 
         Add denatured AMPLICON to separate Microwell Plate (MWP) 
containing oligonucleotide  probe (100 µL  of  CT/NG HYB) specific for the 
CT, NG  or IC targets. The biotin labeled amplicon is captured by the probe - 
coated MWP. Incubate for  an hour at 37°C 
DETECTION REACTION 
           Following the hybridization reaction, the MWP is washed to remove any 
unbound material and an Avidin – horseradish peroxidase conjugate (AV-
HRP) (100µL) is added to each well of the MWP. The Avidin –horseradish 
peroxidase conjugate binds to the biotin – labelled amplicon hybridized by the 
plate -bound oligonucleotide probes. The MWP is washed again to remove 
unbound conjugate and a substrate solution containing 3,3´5,5´ 
tetramethylbenzidine (TMB) is added to the wells. In the presence of hydrogen 
peroxide, the bound horseradish peroxidase catalyzes the oxidation of TMB to 
form a coloured complex. 
          The reaction is stopped by addition of a weak acid, (100µL STOP) and 
the    absorbance at 450 nm is measured using an automated microwell plate 
reader.  Within hour of adding the STOP, record the absorbance value for each 
patient specimen and control tested. 
 
 
RESULTS           
A.CT RESULT: Interpretation of Results without Internal Control Detection 
A450 Interpretation  
<0.2 C. trachomatis  DNA not detected 
≥ 0.8 C. trachomatis DNA detected 
≥0.2- <0.8 Equivocal. 
 
 Interpretation of Results –With Internal Control Detection 
CT Result  
A450 
IC Result 
A450 
Interpretation 
<0.2 ≥0.2 C.trachomatis not 
detected 
<0.2 <0.2 Inhibitory specimen 
  For valid run, Specimen with A450 >0.8 are interpreted as positive for 
C.trachomatis regardless of the IC result. 
B. NG  Result : Interpretation of Results without Internal Control detection 
A450 Interpretation  
<0.2 N.gonorrhoeae DNA not detected 
≥0.2 N.gonorrhoeae DNA detected.  
 
 
Interpretation of Results –With Internal Control Detection 
CT Result IC Result Interpretation 
A450 A450 
<0.2 ≥0.2 N.gonorrhoeae  DNA  not detected
<0.2 <0.2 Inhibitary Specimen 
≥0.2 Any N.gonorrhoeae DNA detected 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   AIMS AND OBJECTIVES 
 
1. To study the prevalence of Chlamydia trachomatis and Neisseria 
gonorrhoeae infections  in patients attending the Out-Patient Department 
of  Institute of Venereology, using AMPLICOR CT/NG Polymerase 
chain reaction. 
2. To study the prevalence of Chlamydia trachomatis and Neisseria 
gonorrhoeae infections among HIV positive patients in the study group. 
3. To study about the age distribution, socioeconomic background, 
educational level and marital status among the patients in the study 
group. 
4. To compare the sensitivity and specificity of AMPLICOR CT/NG 
Polymerase chain reaction with  Culture for  Gonococci and IgM ELISA 
test for Chlamydia trachomatis. 
 
 
 
 
                                      
MATERIALS AND METHODS 
STUDY DESIGN: 
     Prospective observational study. 
SAMPLE: 
     The study population comprised of all male and female patients attending 
the out patient department(OPD) of Institute of Venereology, Government  
General Hospital, Chennai -3 from March 1,2007 to February 29, 2008. 
INCLUSION CRITERIA 
1. All patients attending the OPD irrespective of symptoms. 
2. No antibiotics  taken four weeks prior to examination. 
3. Non-Pregnant females. 
     During the study period 280 males and 270 females, a total of 550 patients 
were enrolled. 
METHODS: 
     The study patients were interviewed regarding their age, educational status, 
occupation,marital status, presenting complaints, sexual history, past history of 
venereal diseases and treatment taken. 
          All the patients underwent a complete physical examination and genital 
examination. All these patients were clinically analysed for the genital 
manifestation and supported by laboratory diagnosis.  
         All patients were screened for Chlamydia trachomatis and Neisseria 
gonorrhoeae infections using Roche AMPLICOR CT/NG Polymerase chain 
reaction. 
    For  AMPLICOR CT /NG PCR Specimens collected were 1)First catch 
30ml of urine from both sexes,2)Endocervical swab from females, 3)Urethral 
swab from males.  In addition, following investigations  were done for all 
patients. 
1)Blood for VDRL and TPHA. 
2)ELISA for HIV and CD4 cell count in HIV positive patients. 
3)Urine -Albumin, sugar, deposits. 
4)Culture for Gonococci –Urine,urethral swab (males), Endocervical 
swab(females). 
5)IgM ELISA for Chlamydia trachomatis.  
6)Screening for HBsAg and Anti HCV antibodies. 
7)Ultrasound abdomen for females. 
         In cases of genital discharge following tests were done.   
1)Wet film for Trichomonas Vaginalis and clue cells (females).  
2)10% KOH Preparation for Candida albicans. 
3)Gram’s stain of vaginal smear, endocervical smear to identify Neisseria 
gonorrhoeae, Lactobacillus, clue cells, candidal hyphae and 
polymorphonuclear leucocytes. Gram’s stain of male urethral smear for 
gonococci,candidal hyphae and polymorphonuclear leucocytes. 
       In addition, for females  pH of the genital discharge,Whiff test by adding 
10% KOH to the genital discharge were done.In case of genital ulcers 
following tests were done. 
1) Dark field examination for treponema pallidum. 
2) Gram stain for Haemophilus ducreyi and candida. 
3) Tissue smear and Leishman’s stain for Donovan bodies.  
4) Tzanck test for multinucleated giant epithelial cells. 
5) Ziehl-Neelsen staining for Mycobacterium tuberculosis. 
6) Wet mount for amoebic infestations. 
            In case of genital growth, Histo-pathological examination of biopsy 
specimen was done for appropriate cases. Urine culture and sensitivity was 
done for needed patients.Liver function tests, complete blood count, renal 
function test,random blood sugar, X-ray chest, ECG,  Sputum examination for 
AFB, Mantoux test, were also done for needed patients.In needed symptomatic 
patients opinion from concerned specialists such as Dermatology, Obstetrics & 
Gynaecology, Dental, Opthalmology, Chest Clinic, Cardiology, Neurology, 
Nephrology, Urology and gastroenterology were obtained.Patients were 
offered standard treatment  according to clinical condition and prophylaxis for 
opportunistic infections. 
                                          RESULTS 
Total number of patients enrolled in the study group - 550 . 
Total number of Males    -280. 
Total number of Females -270. 
 
Table-1: Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae 
infections in the study group 
 
 Males (n-280) Females (n-270) 
Number Percentage% Number Percentage %Neisseria gonorrhoeae 
infections 
 41 14.64 36 13.34 
Chlamydia 
trachomatis infections 
10 3.57 10 3.70 
 
            Prevalence of Gonococcal infections(Males –41, Females –36) was 
high compared to Chlamydia trachomatis infections (Males-10, Females –10) 
among 280 men and 270 women tested.  
                  In gonococcal infections men (14.64%), were more commonly 
infected than women (13.34%). In Chlamydial infections females (3.70%) were 
more commonly infected than males (3.57%).  
  
 
 
 
TABLE- 2: Prevalence of Chlamydia trachomatis and Neisseria 
gonorrhoeae infections  among HIV positive patients  
In the study group HIV was positive in Males –100  and  Females –100 
 
 HIV Positive Males 
N-100 
HIV  Positive Females 
N-100 
 Number Percentage 
% 
Number Percentage 
% 
Neisserria gonorrhoeae 
infections 
14 14 7 7 
Chlamydia trachomatis 
Infections 
3 3 1 1 
 
             In HIV positive patients also, prevalence of gonococcal infections  (m-
14%, f-7%) was high compared to chlamydia trachomatis (m-3%, f-1%) 
infections. Prevalence of both gonococcal and chlamydial infections was high 
in HIV positive males(NG-14%,CT-3%) compared to HIV positive 
females.(NG-7%,CT-1%). 
 
  
 
 
 
 
 
 
Table -3: Number of positivity in  urine and urethral swab specimens of 
affected males 
 
 
Neisseria gonorrhoea 
Infections 
n-41 
Chlamydia trachomatis 
infections 
n-10 
Both NG and CT 
n-4 
Urine Swab Both Urine Swab Both Urine Swab Both 
16 13 12 7 2 1 3 - 1 
 
          In Gonococcal and Chlamydial infections,  urine specimens showed 
more positivity than urethral swab specimens. 
 
Table -4 : Number of positivity in urine and endocervical swab 
specimens of  affected females 
Neisseria gonorrhoea 
infections 
n-36 
Chlamydia trachomatis
infections 
n-10 
Both NG and CT 
 
n-7 
Urine Swab Both Urine Swab Both Urine Swab Both 
15 13 8 3 6 1 2 5 - 
 
             In Gonococcal infections urine specimens  showed more positivity  
than endocervical swab specimens. In Chlamydial infections & concomitant 
infections of both CT and NG, endocervical swab specimens  showed more 
positivity than urine specimens. 
Table-5a :Asymptomatic Cases in Chlamydial Infection 
 
                                    Total Positive  M-10,  F-10 
 
HIV 
(M-3 ,F-1) 
NON HIV 
(M-7, F-9) 
 
Asymptomatic patients 
Number Percentage 
% 
Number Percentage 
% 
 
Males -2 (20%) 
2 66.67 - - 
 
Females –4 (40%) 
1 100 3 33.34 
 
Table –5b: Asymptomatic cases in Gonococcal Infection 
 
                         Total Positive    M-41, F-36 
 
HIV 
(M-14 ,F-7) 
NON HIV 
(M-27, F-29) 
 
Asymptomatic 
patients Number Percentage 
% 
Number Percentage 
% 
Males –12(29.26%) 8 57.14 4 14.8 
Females –
10(27.78%) 
 
4 57.14 6 20.68 
      Asymptomatic Gonococcal infection was common in males (29.26%) than 
females (27.78%). Asymptomatic Chlamydial infection was more common in 
females (40%) than males (20%).In males, asymptomatic gonococcal and 
chlamydial infections were common in HIV positive patients (NG-57.14%, 
CT-66.67%) compared to HIV negative patients (NG-14.8%  CT-0%). 
       In females also, asymptomatic gonococcal and chlamydial infections was 
common in HIV positive patients (NG-57.14%, CT-100%) compared to HIV 
negative patients (NG –20.68%, CT-33.34%). 
 
TABLE-6:  Evaluation of AMPLICOR CT/NG PCR Gonococcal 
infections in  affected males with reference to culture. 
 
CULTURE FOR 
GONOCOCCI 
PCR 
Positive Negative 
TOTAL 
Positive 19 22 41 
Negative 0 239 239 
 19 261 280 
 
                 In gonococcal infection positive males, AMPLICOR CT /NG PCR 
had sensitivity ,specificity,positive predictive and negative predictive values of 
100%,92%,46%,100% respectively. 
TABLE-7: Evaluation of AMPLICOR CT /NG PCR with reference to 
culture for gonococcal infections in affected  females. 
PCR CULTURE FOR 
GONOCOCCI 
TOTAL 
 Positive Negative  
Positive 16 20 36 
Negative 0 234 234 
 16 254 270 
 
         In gonococcal infection  positive females, AMPLICOR CT /NG PCR 
had sensitivity, specificity, positive predictive value and negative predictive 
values of 100%, 92%,44% and 100% respectively. 
                                                                                                                         
TABLE-8 : Evaluation of AMPLICOR CT /NG PCR with reference to 
IgM ELISA for Chlamydia trachomatis infection positive males 
IgM ELISA for 
C.trachomatis 
PCR 
Positive Negative 
TOTAL 
Positive 7 3 10 
Negative - 270 270 
 7 273 280 
 
             In Chlamydia trachomatis infection positive males, AMPLICOR 
CT/NG PCR had sensitivity  specificity, positive predictive value, and negative 
predictive value of 100%, 99%, 70% and 100% respectively. 
Table-9:Evaluation of AMPLICOR CT /NG PCR with reference to IgM 
ELISA for Chlamydia trachomatis infection positive females. 
IgM ELISA for 
Chlamydia 
PCR 
Positive Negative 
TOTAL 
Positive 5 5 10 
Negative 0 260 260 
 5 265 270 
 
        In Chlamydia trachomatis infection positive females, AMPLICOR CT/NG 
PCR had sensitivity, specificity, positive predictive value and negative 
predictive value of 100%, 98%, 50% and 100% respectively. 
 
 
 
TABLE-10a:  Age Distribution of Chlamydia trachomatis and 
Neisseria gonorrhoeae infections in affected  males. 
AGE Gonococcal infections (n-41) Chlamydial infections (n-10)
 Number Percentage% Number Percentage % 
16-19 - - 1 10 
20-29 18 43.90 5 50 
30-39 12 29.26 3 30 
40-49 11 26.82 1 10 
More 
than 50 
- - - - 
 
         Majority of Gonococcal (43.90%) and Chlamydia trachomatis 
(50%)infections  positive patients belonged to 20-29 years age group. 
 
TABLE-10b:  Age distribution of Chlamydia trachomatis and Neisseria 
gonorrhoeae infections in  affected females. 
AGE Gonococcal infections (n-36) Chlamydial infections (n-10) 
 Number Percentage% Number Percentage% 
16-19 - - - - 
20-29 17 47.23 6 60% 
30-39 14 38.89 3 30% 
40-49 4 11.12 1 10% 
More 
than 50 
1 2.78 - - 
 
      Majority of gonococcal (47.23%) and Chlamydial (60%) infections 
positive females belonged to 20-29 years age group. 
 
 
 
TABLE -11a: Socio economic status of  affected males 
Monthly Income 
(in rupees) 
Gonococcal infections 
(n-41) 
Chlamydial infections 
(n-10) 
 Number 
 
Percentage% Number Percentage%
<1000 34 82.92 9 90% 
1000-1999 5 12.19 1 10% 
2000-4999 1 2.43 - - 
>5000 1 2.43 - - 
 
       Majority of  affected males belonged to lower socioeconomic status 
(NG-82.92%, CT-90%) i.e. less than Rs.1000 per month. 
 TABLE- 11b: Socio –Economic Status of affected Females                                                  
Monthly Income 
(in rupees) 
Gonococcal infections 
(n-36) 
Chlamydial infections 
(n-10) 
 Number 
 
Percentage% Number Percentage%
<1000 28 77.78 8 80 
1000-1999 6 16.67 2 20 
2000-4999 1 2.78   
>5000 1 2.78   
 
      Majority of affected females belonged to lower socioeconomic status 
(NG-77.78%,CT-80%) i.e. less than Rs.1000 per month. 
 
 
 
 
TABLE-12a:  Educational Status among  affected males                                      
Educational Status Gonococcal infections 
(n-41) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Uneducated 8 19.51 1 10 
1-5th 12 29.26 3 30 
6-10th 19 46.34 4 40 
11-12th 2 4.87 2 20 
College - - - - 
 
       Majority of affected males had High School education (NG-46.34%, CT-
40%). 
 
TABLE-12b :Educational Status among affected  females                                                 
Monthly Income 
(in rupees) 
Gonococcal infections 
(n-36) 
Chlamydial infections 
(n-10) 
 Number 
 
Percentage% Number Percentage%
Uneducated 8 22.23 2 20 
1-5th 10 27.78 3 30 
6-10th 17 47.23 3 30 
11-12th 1 2.78 2 20 
College - - - - 
 
           Majority of  affected females had high school education (NG-47.23%, 
CT-30%). 
 
 
 
 
TABLE- 13a:    Marital Status among affected Males 
Marital Status Gonococcal infections  
(n-41) 
Chlamydial infections  
(n-10) 
 Number Percentage % Number Percentage % 
Married 22 53.65 7 70% 
Single 19 46.34 3 30% 
Divorced 
/Separated 
- - -  
Widow - - - - 
 
       Majority of  affected males in the study group were married (NG-53.65%, 
CT-70%). 
 
 
TABLE- 13b : Marital Status among affected females 
Marital Status Gonococcal infections  
(n-36) 
Chlamydial infections  
(n-10) 
 Number Percentage % Number Percentage % 
Married 30 83.34 8 80 
Single 1 2.78 2 20 
Divorced 
/Separated 
2 5.56 -  
Widow 3 8.34 - - 
 
       Majority of  affected females in the study group were married (NG-
83.34%, CT-80%). 
 
 
 
 
TABLE- 14a:  Presenting Complaints of the affected males  
Presenting 
Complaints 
Gonococcal infections 
(n-41) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Screening 12 29.26 2 20 
Burning 
Micturition 
22 53.65 8 80 
Genital 
Discharge 
9 21.95 2 20 
Genital Ulcer 3 7.31 3 30 
Growth 
Genitalia 
2 4.87 - - 
Skin rash 3 7.31 - - 
Loss of appetite 3 7.31 1 10 
Genital itching 1 2.43 - - 
Sexual 
dysfunction 
1 2.43 1 10 
 
 
 
            Burning micturition was the main complaint in affected males (NG-
53.65%, CT-80%) followed by genital discharge  (NG-21.95%,CT –20%) and 
genital ulcer (NG-7.31%, CT-30%) . 
29.26% of gonococcal infection positive males and 20% of chlamydia 
trachomatis infection positive males came for screening. 
 
 
 
 
 
 
Table -14b:   Presenting Complaints  of the  affected females 
 
Presenting 
Complaints 
Gonococcal infections 
(n-36) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Screening 10 27.78 4 40 
Genital Discharge 18 50 5 50 
Burning 
Micturition 
7 19.45 4 40 
Growth genitalia 2 5.56 1 10 
Genital Ulcer 3 8.34 - - 
Genital Itching 8 22.23 2 20 
Lower Abd Pain 3 8.34 1 10 
Skin rash 1 2.77 - - 
Loss of appetite 2 5.56 - - 
 
 
             Majority of the affected females visited for Genital discharge  (NG-
50%, CT-50%) followed by burning micturition (NG –19.45%, CT-40%). 
Genital Itching  (NG-22.23%, CT-20%), lower abdominal pain (NG-
8.34%,CT-10%) were the other complaints.40% of chlamydial infection  
positive patients and 27.78% of gonorrhoeae positive patients came for 
screening. 
 
 
 
 
 
 
Table-15a: Clinical Signs in the affected males 
 
Clinical Signs Gonococcal infections 
(n-41) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Urethral discharge 6 14.63 1 10 
Genital Ulcer 4 9.75 3 30 
Genital wart 3 7.31 1 10 
Phimosis 2 4.87 - - 
Vitiligo 2 4.87 - - 
Balanoposthitis 1 2.43 - - 
Pearly Penile 
papules 
1 2.43 - - 
Dermatophytosis 1 2.43 - - 
Folliculitis -  1 10 
Skin rash 1 2.43 - - 
No abnormal 
findings 
24 58.53 4 40 
 
 
          In gonorrhoeae positive males urethral discharge (14.63%) was the most 
common clinical sign followed by genital ulcer (9.75%) and genital wart 
(7.31)%. 
          In Chlamydia trachomatis infection positive males genital ulcer (30%) 
was the most common clinical sign followed by  urethral discharge (10%), 
genital wart (10%) and folliculitis (10%). 
58.53% of N.gonorrhoeae infection positive and 40% Chlamydial infection 
positive patients had no abnormal clinical findings. 
 
 
 Table- 15b: Clinical signs in the affected   females 
 
 
Clinical  
Signs  
Gonococcal infections 
(n-36) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Cervical Erosions 21 58.34 7 70 
Cervical 
Hypertrophy  
6 16.67 1 10 
Soddening of 
vulva 
4 11.12 1 10 
Cervix healthy 9 25 2 20 
Genital ulcer 1 2.78 - - 
Genital wart 1 2.78 1 10 
Mollusum 
contagiosum 
1 2.78 - - 
Bartholin cyst 1 2.78 1 10 
Folliculitis 1 2.78 - - 
 
 
            In gonococcal infection positive female patients, 58.34% had cervical 
erosions, followed by cervical hypertrophy (16.67%), soddening of vulva 
(11.12%), 25% of them had healthy cervix. In Chlamydial infection positive 
females also, cervical erosion (70%) was the most common clinical sign 
followed by cervical hypertrophy (10%), soddening of vulva (10%), genital 
wart (10%), Bartholin cyst (10%) and  20% had healthy cervix. 
 
 
 
 
 
 
 
Table -16a: Other associated STDs among Neisseria gonorrhoeae and 
Chlamydia trachomatis infection positive men 
 
 
Other Associated 
STDs 
Gonococcal infections 
(n-41) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Chlamydial 
infection  
3 7.31 - - 
Gonorrhoeae - - 3 30 
Candidiasis 1 2.43 - - 
Genital wart 3 7.31 1 10 
Molluscum 
Contagiosum 
- - - - 
Herpes genitalis 3 7.31 3 30 
Syphilis (ELS-1) 
              LLS-1) 
2 4.87 - - 
HBSAg 1 2.43 - - 
Trichomonas 
Vaginalis 
- - - - 
More than two 
STDs 
- - - - 
 
       In Gonorrhoeae positive males, most common associated STIs were 
Chlamydia tracthomatis infection (7.31%), Genital wart (7.31%) and Herpes 
genitalis (7.31%). 
        In Chlamydia trachomatis infection positive females,  most common 
associated STIs were Gonorrrhoea (30%), and Herpes genitalis (30%). 
 
 
 
 
 
 
 
 
Table - 16b: Other associated STDs among Neisseria gonorrhoeae and 
Chlamydia trachomatis infections positive women 
 
Other Associated 
STDs 
Gonococcal infections 
(n-36) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Chlamydial 
infection  
7 19.45  - 
Gonorrhoeae - - 7 70 
Candidiasis  9 25 1 10 
Genital Wart 1 2.78 1 10 
Molluscum 
Contagiosum 
1 2.78 - - 
Herpes genitalis 1 2.78 - - 
Syphilis - - - - 
HBs Ag - - - - 
Trichomonas 
Vaginalis 
4 11.12 3 30 
Bacterial Vaginosis 15 41.67 4 40 
More than two 
STDs 
8 22.23 3 30 
 
      In gonococcal  infection positive women,  Bacterial vaginosis (41.67%)  
was the commonest STI followed by candidiasis (25%) and Chlamydial 
infections (19.45%). 
        In Chlamydial infection positive women, N.gonorrhoea (70%) was the 
commonest STI followed by Bacterial vaginosis (40%) and trichomoniasis 
(30%). 
 
 
 
 
 
Table -17: Nature of Genital Discharge among affected females 
 
Nature  
of Discharge  
Gonococcal infections 
(n-36) 
Chlamydial infections 
(n-10) 
 Number Percentage% Number Percentage%
Mucopurulent 18 50 4 40 
Mucoid 11 30.56 3 30 
Curdy white 3 8.34 - - 
Frothy 4 11.12 3 30 
 
        Majority of the  affected women had mucopurulent  vaginal discharge 
(NG-50%, CT-40%). 
TABLE-18a:CD4 COUNT – In HIV Positive males 
 
CD4 Count Gonococcal infections 
(n-14) 
Chlamydial infections 
(n-3) 
 Number Percentage% Number Percentage%
Less than 300 4 28.57 1 33.34 
 
More than 300 10 71.42 2 66.67 
 
       71.42% of gonococcal infection positive males and 66.67% Chlamydial 
infection positive males had CD4 count  of more than 300. 
Table 18b :  CD4 count in HIV Positive females 
 
CD4 Count Gonococcal infections 
 (n-7) 
Chlamydial infections 
(n-1) 
 Number Percentage% Number Percentage%
Less than 300 2 28.57 - - 
 
More than 300 5 71.42 1 100% 
 
      71.42% of Gonorrhoea positive females and  100% of  Chlamydia 
trachomatis infection positive females had CD4 count of more than 300. 
DISCUSSION 
         During the study period, 550 patients were enrolled for Multiplex 
Amplicor CT/NG PCR study. Out of 550 patients 280 were males and 270 
were females. 
             14.64% of males and 13.34% of  females were positive for gonococcal 
infection. 3.57% of males and 3.70% of females were positive for Chlamydial 
infections. This was comparable with the  study done by William C et al in 
which 3.67% males and 4.74% of females were positive for C. trachomatis 
infections73. 
              Gonococcal infections (males –14.64%, females –13.34%) were more 
common than Chlamydial infections (males –3.57% females 3.70%). 
In gonococcal infections  men(14.64%), were more commonly infected than 
women (13.34%). In Chlamydial infections females (3.70%) were more 
commonly infected than males (3.57%). This result correlates with William C 
et al  study in which 4.74% of females were positive for Chlamydial infection 
compared to males of  3.67%  73. 
             In the study 100 HIV positive males and 100 positive females were 
enrolled. In HIV positive patients also, prevalence of gonococcal infection(M-
14%,F-7%)  was high compared to chlamydia trachomatis  (M-3%, F-1%) 
infections. Prevalence of both gonococcal and chlamydial infection was high in 
HIV positive males  ( NG-14%, CT-3%), compared to HIV positive females 
(NG-7%, CT-1%). 
              Urine PCR (m-16,f-15)showed more positivity than male urethral 
(13)and female endocervical swab PCR(13) in gonococcal infection positive 
patients. In Chlamydial infection positive males urine PCR(7) showed more 
positivity than urethral swab PCR(2), but in females endocervical swab PCR(6) 
showed more positivity than urine PCR(3). 
              Asymptomatic gonococcal infection was common in  affected males (29.26%) 
when compared to  affected females (27.78%). Asymptomatic Chlamydial infection was 
common in affected females (40%) than affected males (20%).Asymptomatic gonococcal 
(M-57.14%, F-57.14%) and chlamydial infections (M-66.67%, F-100%) were common in 
HIV positive patients compared to HIV negative patients. In HIV positive  patients, 
asymptomatic gonococcal and chlamydial infections were common in females (NG-57.14%, 
CT-100%) than males (NG-57.14%, CT-66.67%). 
                 In gonococcal infection  positive males, AMPLICOR CT/NG PCR 
had sensitivity, specificity, positive predictive value and negative predictive 
value of 100%, 92%, 46% and 100% respectively. In gonococcal infection 
positive females, AMPLICOR CT/NG PCR had sensitivity, specificity, 
positive predictive value and negative predictive value of 100%, 92%, 44% and 
100%  respectively compared with N.gonorrhoeae Culture. 
                 In Chlamydia trachomatis infection positive males, AMPLICOR  CT 
/NG PCR had sensitivity, specificity, positive predictive value and negative 
predictive value of 100%, 99%, 70% ad 100% respectively compared with IgM 
ELISA. In C. trachomatis  infection positive females, the sensitivity, 
specificity, positive predictive value, and negative predictive value of 
AMPLICOR CT/NG PCR were 100%, 98%, 50% and 100% respectively. 
           Majority of Gonococcal (43.90%) and Chlamydial (50%) infection 
positive males belonged to 20-29 years age group, similarly in affected females 
majority belonged to 20-29 years age group (NG-47.23%, CT- 60%) which 
was similar to many studies 1, 9, 19-22 in India and worldwide. Majority of 
affected males  belonged to lower socioeconomic status (NG-82.92%,CT-
90%). In  affected females also, majority  belonged to  lower socioeconomic 
status (NG-77.78%, CT-80%) . 
               Majority of affected males had high school education (NG-46.34%, 
CT-40%). Similarly, majority of affected females had high school education 
(NG-47.23%, CT-30%). 53.65% of gonococcal and 70% of  Chlamydial 
infection affected males were married. Majority of the affected females in the 
study group were married (NG-83.34%, CT-80%). 
            Burning micturition was the main complaint in affected males (NG-
53.65%,CT-80%) followed  by  genital discharge (NG-21.95%, CT-20%) and 
genital ulcer (NG-7.31%, CT-30%). 29.26% of gonococcal and 20% of 
Chlamydial infection affected male patients came for screening. In affected 
females, genital discharge (NG-50%, CT –50%) was the main complaint 
followed by burning micturition (NG-19.45%, CT-40%) and genital itching 
(NG-22.23%,CT-20%). 40% of Chlamydial and 27.78% gonococcal infection 
positive female patients came for screening.  
          In gonococcal infection positive males urethral discharge (14.63%) was 
the most common clinical sign followed by genital ulcer (9.75%). In 
Chlamydial infection affected males genital ulcer (30%) was the most common 
clinical sign followed by urethral discharge (10%). 
                In affected females, cervical erosion was the main clinical 
finding(NG-58.34%, CT-70%). 50% of gonococcal and 40% of Chlamydial 
infection positive females had mucopurulent vaginal discharge. 
            In gonococcal infection positive males, most common associated STIs 
were C. trachomatis infection (7.31%), genital wart (7.31%) and Herpes 
genitalis (7.31%). In  Chlamydia trachomatis infection  affected males, most 
common associated STIs were N. gonorrhoeae infection (30%) and Herpes 
genitalis(30%). 
              In gonococcal infection positive women, Bacterial vaginosis (41.67%) 
was the commonest associated STI followed by candidiasis (25%) and C. 
trachomatis infection (19.45%). In C. trachomatis infection positive women, 
gonococcal infection (70%) was the commonest associated STI followed by 
bacterial vaginosis (40%) and Trichomoniasis (30%). 
          Gonococcal infection was detected in 30% of men and 70% of females 
with C. trachomatis infection which was similar to study by Philip DJ. et al31.                         
           Majority of HIV positive males had CD4 count of more than 300 (NG-
71.42%, CT-66.67%). In the HIV positive females also, majority had CD4 
count of more than 300 (NG-71.42%, CT –100%). 
 
 
 
 
  
 
 
CONCLUSION 
1. Gonococcal infections (males –14.64%, females –13.34%) was more 
common than Chlamydia trachomatis (males-3.57%, females –3.70%) 
infections. Gonococcal infection was more common in men (14.64%) 
compared to women (13.34%). Chlamydial infection was more common 
in women (3.70%) when compared to men (3.57%). 
2. In HIV positive patients also, gonococcal infections  (M-14%, F-
7%),were more common than chlamydial infections (M-3%, F-11%). 
3. AMPLICOR CT /NG PCR for urine specimens (M-16, F-15) was highly 
sensitive than male urethral (13) and female endocervical swab (13) 
specimens in detecting gonococcal infections. In Chlamydial infections, 
urine PCR (7) was highly sensitive than urethral swab PCR (2) in males 
but in females, endocervical swab PCR(6) was more sensitive than urine 
PCR (3). 
4. Asymptomatic gonococcal infection was common in affected males 
(29.26%) when compared to affected females (27.78%). Asymptomatic 
Chalmydial infection was common in affected females (40%) compared 
to affected males(20%).Asymptomatic gonococcal (M-57.14%, F-
57.14%) and chlamydial   infections (M-66.67%, F-100%) were 
common in HIV positive patients compared to HIV negative patients. 
5. AMPLICOR CT/NG PCR had 100% sensitivity in detecting gonococcal 
infections compared with gonococcal culture and also had 100% 
sensitivity in detecting chlamydial infections compared with IgM  
ELISA for C. trachomatis. 
6. Majority of gonococoal (M-43.90%, F-47.23%) and Chlamydial (M-
50%, F-60%)  infection positive patients belonged to 20-29 years age 
group. Majority of the affected  patients belonged to lower 
socioeconomic status. 
7. Burning micturition (NG-53.65%, CT-80%) was the main complaint in 
affected males and genital discharge (NG-50%,CT-50%) was the main 
complaint in affected females. In gonococcal infection positive males, 
urethral discharge (14.63%) was the common clinical finding and in 
chlamydial  infection positive males genital ulcer (30%) was the 
common clinical finding .Cervical erosion (NG-58.34%, CT-70%) was 
the common clinical finding in affected  females. 
8. In Chlamydial infection positive patients, gonococcal infection was the 
most commonest associated STI (M-30%, F-70%). In gonococcal 
infection positive males, C. trachomatis (7.31%) was the commonest 
associated STI and in females, Bacterial vaginosis (41.67%) was the 
commonest  associated STI. 
                AMPLICOR  CT/NG PCR had 100% sensitivity in detecting 
gonococcal and chlamydial infections. PCR screening will diagnose 
asymptomatic cases of both gonococcal and chlamydial infections. 
                 Since coinfection rate of gonococcal and chlamydial infection 
were high, all cases of gonorrhoeae should be treated presumptively for 
chlamydial infection as recommended by CDC and WHO. 
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